The role of novel anticoagulants in the management of venous thromboembolic disease

Dalene Bott Kitslaar, Waldemar E. Wysokinski, Robert D. McBane

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The introduction of oral direct coagulation factor inhibitors is dramatically changing the landscape of anticoagulation delivery in patients experiencing or at risk for a thrombotic event. These novel anticoagulants can be particularly attractive for health care providers, as they deliver therapeutic anticoagulation at a fixed dose, require no routine coagulation monitoring, and have few drug interactions and no food restrictions. Herein, we will review the role of these novel anticoagulants for acute venous thromboembolism treatment, primary and secondary venous thromboembolism prevention, and management during the periprocedural period.

Original languageEnglish (US)
Article number326
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume16
Issue number8
DOIs
StatePublished - Aug 2014

Keywords

  • Apixaban
  • Dabigatran
  • Edoxaban
  • Novel anticoagulants
  • Rivaroxaban
  • Venous thromboembolism treatment (VTE)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The role of novel anticoagulants in the management of venous thromboembolic disease'. Together they form a unique fingerprint.

Cite this